小剂量舒利迭治疗中度成人支气管哮喘的临床试验  

Clinical Efficiency of Low Dose Seretide in the Treatment of Moderate Asthma in Adults

作　　者：张铁锋[1] 修清玉[1] 黄海[1] 叶俊[1] 

机构地区：[1]第二军医大学附属长征医院呼吸科,上海200003

出　　处：《医学临床研究》2009年第8期1400-1402,共3页Journal of Clinical Research

摘　　要：【目的】了解小剂量舒利迭（丙酸氟替卡松100μg，沙美特罗50μg）对中度成人支气管哮喘的临床治疗效果。【方法】采用随机、平行、对照的方法，观察40例成人中度支气管哮喘患者使用小剂量舒利迭治疗后4、8、12周的FEV1、PEF值、ACT（athma control test）症状评分、平均每日万托林用量，12周内哮喘恶化的次数，并与治疗前和对照组进行比较。【结果】舒利迭组患者治疗后各项指标较治疗前有显著改善（P〈0．01），较对照组有显著改善（P〈0．01），12周内哮喘恶化次数较对照组明显减少（P〈0．01），控制率明显高于对照组（P〈0．01）。【结论】小剂量舒利迭治疗成人中度支气管哮喘疗效良好，选用小剂量舒利迭可控制成人哮喘，节约成本和减少副反应。[Objective]To investigate the clinical efficiency of low dose seretide（flurieasone 100 ug and salmetero 150 ug） in the treatment of moderate asthma in adult, fMethods] Low dose seretide was given to 40 enrolled patients. At 4-, 8- and 12-week after low dose seretide treatment of all patients, FEV1, PEF, ACT （asthma control test） scores, the daily dosage of ventolin daily and the times of asthma exacerbation were observed and compared to the normal control by randomized, paralleled and contrasted method. The results were analyzed by χ2 test and ANOVA. [Results]FEV1, PEF and ACT scores after 4-, 8- and 12-week treatment were improved, significantly compared to the baseline value and the control group （ P〈0.01）. The times of exacerbation were also deceased significantly during the observation period compared to the control group. And the control rate of asthma was higher than that of the control group significantly. [Conclusion] Low dose seretide is effective for the treatment of moderate asthma in adult. It can save cost and reduce the adverse reaction.

关 键 词：哮喘/药物疗法 

分 类 号：R562.25[医药卫生—呼吸系统]